Conventional therapeutics with antiangiogenic activity

Antiangiogenic Cancer Therapy

Volumn , Issue , 2007, Pages 301-328

  Hafner, Christian ^a   Vogt, Thomas ^a   Reichle, Albrecht ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58649120086     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420004298     Document Type: Chapter

References (241)

1. Leaf, C., Why we’re losing the war on cancer (and how to win it). Fortune, 149, 76-82, 84-86, 88, 2004.
2. Boehm, T. et al., Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature, 390, 404-407, 1997.
3. Graham, C.H. et al., Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents. J Natl Cancer Inst, 86, 975-982, 1994.
4. Hanahan, D. and Weinberg, R.A., The hallmarks of cancer. Cell, 100, 57-70, 2000.
5. Carmeliet, P. and Jain, R.K., Angiogenesis in cancer and other diseases. Nature, 407, 249-257, 2000.
6. Hla, T. and Neilson, K., Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA, 89, 7384-7388, 1992.
7. Yang, V.W. et al., Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res, 58, 1750-1753, 1998.
8. Fukuda, R., Kelly, B., and Semenza, G.L., Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res, 63, 2330-2334, 2003.
9. Zha, S. et al., Cyclooxygenases in cancer: progress and perspective. Cancer Lett, 215, 1-20, 2004.
10. Dubois, R.N. et al., Cyclooxygenase in biology and disease. FASEB J, 12, 1063-1073, 1998.
11. Fosslien, E., Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci, 30, 3-21, 2000.
12. Chen, C.C. et al., Tumor necrosis factor-alpha-induced cyclooxygenase-2 expression via sequential activation of ceramide-dependent mitogen-activated protein kinases, and IkappaB kinase 1=2 in human alveolar epithelial cells. Mol Pharmacol, 59, 493-500, 2001.
13. Liu, X.H. et al., Cycloxygenase-2 suppresses hypoxia-induced apoptosis via a combination of direct and indirect inhibition of p53 activity in a human prostate cancer cell line. J Biol Chem, 280, 3817-3823, 2004.
14. Diperna, C.A. et al., Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma. J Thorac Cardiovasc Surg, 126, 1129-1133, 2003.
15. Basu, G.D. et al., Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res, 2, 632-642, 2004.
16. Fenwick, S.W. et al., The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology, 125, 716-729, 2003.
17. Hu, P.J. et al., Chemoprevention of gastric cancer by celecoxib in rats. Gut, 53, 195-200, 2004.
18. Kern, M.A. et al., Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis, 25, 1193-1199, 2004.
19. Narayanan, B.A. et al., Suppression of N-methyl-N-nitrosourea=testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s). Clin Cancer Res, 9, 3503-3513, 2003.
20. Narayanan, B.A. et al., Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res, 10, 7727-7737, 2004.
21. Masferrer, J.L. et al., Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res, 60, 1306-1311, 2000.
22. Raut, C.P. et al., Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. Cancer Biol Ther, 3, 2004.
23. Form, D.M. and Auerbach, R., PGE2 and angiogenesis. Proc Soc Exp Biol Med, 172, 214-218, 1983.
24. Tatsuguchi, A. et al., Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue. Hum Pathol, 35, 488-495, 2004.
25. Ma, L., del Soldato, P., and Wallace, J.L., Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: shifting the angiogenic balance. Proc Natl Acad Sci USA, 99, 13243-13247, 2002.
26. Kobayashi, H. et al., JTE-522, a selective COX-2 inhibitor, interferes with the growth of lung metastases from colorectal cancer in rats due to inhibition of neovascularization: a vascular cast model study. Int J Cancer, 112, 920-926, 2004.
27. Tsujii, M. et al., Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell, 93, 705-716, 1998.
28. Majima, M. et al., Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Pharmacol, 130, 641-649, 2000.
29. Cheng, T. et al., Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Invest Ophthalmol Vis Sci, 39, 581-591, 1998.
30. Williams, C.S. et al., Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest, 105, 1589-1594, 2000.
31. Wei, D. et al., Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res, 64, 2030-2038, 2004.
32. Nor, J.E. et al., Up-regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res, 61, 2183-2188, 2001.
33. Nor, J.E. et al., Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol, 154, 375-384, 1999.
34. Dimmeler, S. and Zeiher, A.M., Akt takes center stage in angiogenesis signaling. Circ Res, 86, 4-5, 2000.
35. Gately, S. and Li, W.W., Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol, 31, 2-11, 2004.
36. Dormond, O. et al., Prostaglandin E2 promotes integrin alpha V beta 3-dependent endothelial cell adhesion, rac-activation, and spreading through cAMP=PKA-dependent signaling. J Biol Chem, 277, 45838-45846, 2002.
37. Ruegg, C., Dormond, O., and Mariotti, A., Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis. Biochim Biophys Acta, 1654, 51-67, 2004.
38. Dohadwala, M. et al., Autocrine=paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem, 277, 50828-50833, 2002.
39. Callejas, N.A. et al., Expression of cyclooxygenase-2 promotes the release of matrix metalloproteinase-2 and -9 in fetal rat hepatocytes. Hepatology, 33, 860-867, 2001.
40. Vaday, G.G. et al., Transforming growth factor-beta suppresses tumor necrosis factor alphainduced matrix metalloproteinase-9 expression in monocytes. J Leukoc Biol, 69, 613-621, 2001.
41. Masson, V. et al., Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes. FASEB J, 19, 234-236, 2005.
42. Voest, E.E. et al., Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst, 87, 581-586, 1995.
43. Stolina, M. et al., Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol, 164, 361-370, 2000.
44. Pai, R. et al., Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med, 8, 289-293, 2002.
45. Kedar, D. et al., Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice. Clin Cancer Res, 8, 3592-3600, 2002.
46. Rodrigues, S. et al., Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling. FASEB J, 17, 7-16, 2003.
47. Pore, N. et al., PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Res, 63, 236-241, 2003.
48. Daniel, T.O. et al., Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res, 59, 4574-4577, 1999.
49. Murohara, T. et al., Vascular endothelial growth factor=vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation, 97, 99-107, 1998.
50. Nataraj, C. et al., Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse. J Clin Invest, 108, 1229-1235, 2001.
51. Lang, S. et al., Impaired monocyte function in cancer patients: restoration with a cyclooxygenase-2 inhibitor. FASEB J, 17, 286-288, 2003.
52. Baratelli, F.E. et al., Prostaglandin E2-dependent enhancement of tissue inhibitors of metalloproteinases-1 production limits dendritic cell migration through extracellular matrix. J Immunol, 173, 5458-5466, 2004.
53. Johnsen, J.I. et al., Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal antiinflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res, 64, 7210-7215, 2004.
54. Pruthi, R.S., Derksen, J.E., and Moore, D., A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. BJU Int, 93, 275-278, 2004.
55. Wang, Z., Fuentes, C.F., and Shapshay, S.M., Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell. Laryngoscope, 112, 839-843, 2002.
56. Oyama, K. et al., ACOX-2 inhibitor prevents esophageal inflammation-metaplasia-adenocarcinoma sequence in rats. Carcinogenesis, 26, 565-570, 2005.
57. Garcia Rodriguez, L.A. and Huerta-Alvarez, C., Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology, 11, 376-381, 2000.
58. Thun, M.J., Henley, S.J., and Patrono, C., Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst, 94, 252-266, 2002.
59. Moran, E.M., Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. J Environ Pathol Toxicol Oncol, 21, 193-201, 2002.
60. Harris, R.E., Beebe-Donk, J., and Schuller, H.M., Chemoprevention of lung cancer by nonsteroidal anti-inflammatory drugs among cigarette smokers. Oncol Rep, 9, 693-695, 2002.
61. Jacobs, E.J. et al., Aspirin use and pancreatic cancer mortality in a large United States cohort. J Natl Cancer Inst, 96, 524-528, 2004.
62. Schernhammer, E.S. et al., A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst, 96, 22-28, 2004.
63. Steinbach, G. et al., The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med, 342, 1946-1952, 2000.
64. Phillips, R.K. et al., A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut, 50, 857-860, 2002.
65. Davis, T.W. et al., Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting. J Pharmacol Exp Ther, 308, 929-934, 2004.
66. Lenz, W. and Knapp, K., [Thalidomide embryopathy.] Dtsch Med Wochenschr, 87, 1232-1242, 1962.
67. Sampaio, E.P. et al., The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis, 168, 408-414, 1993.
68. Singhal, S. et al., Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med, 341, 1565-1571, 1999.
69. Eisen, T. et al., Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer, 82, 812-817, 2000.
70. Macpherson, G.R. et al., Current status of thalidomide and its role in the treatment of metastatic prostate cancer. Crit Rev Oncol Hematol, 46 Suppl, S49-57, 2003.
71. Fine, H.A. et al., Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol, 18, 708-715, 2000.
72. Stebbing, J. et al., The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer, 85, 953-958, 2001.
73. Dredge, K. et al., Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer, 87, 1166-1172, 2002.
74. Kumar, S. et al., Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs. Leukemia, 19, 1253-1261, 2005.
75. D’Amato, R.J. et al., Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA, 91, 4082-4085, 1994.
76. Neben, K. et al., High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res, 7, 2675-2681, 2001.
77. Sampaio, E.P. et al., Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med, 173, 699-703, 1991.
78. Kedar, I., Mermershtain, W., and Ivgi, H., Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy. Int J Cancer, 110, 260-265, 2004.
79. Sleijfer, S., Kruit, W.H., and Stoter, G., Thalidomide in solid tumours: the resurrection of an old drug. Eur J Cancer, 40, 2377-2382, 2004.
80. Gupta, D. et al., Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia, 15, 1950-1961, 2001.
81. Zhang, Z.L., Liu, Z.S., and Sun, Q., Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice. World J Gastroenterol, 11, 216-220, 2005.
82. Fujita, J. et al., Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin Cancer Res, 7, 3349-3355, 2001.
83. Keifer, J.A. et al., Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem, 276, 22382-22387, 2001.
84. Yabu, T. et al., Thalidomide-induced anti-angiogenic action is mediated by ceramide through depletion of VEGF receptors, and antagonized by sphingosine-1-phosphate. Blood, 106, 125-134, 2005.
85. Zhang, H. et al., Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood, 105, 3286-3294, 2005.
86. Lyden, D. et al., Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med, 7, 1194-1201, 2001.
87. Dredge, K. et al., Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res, 69, 56-63, 2005.
88. Hideshima, T. et al., Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 96, 2943-2950, 2000.
89. Haslett, P.A. et al., Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8þ subset. J Exp Med, 187, 1885-1892, 1998.
90. Davies, F.E. et al., Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood, 98, 210-216, 2001.
91. Geitz, H., Handt, S., and Zwingenberger, K., Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology, 31, 213-221, 1996.
92. Juliusson, G. et al., Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol, 109, 89-96, 2000.
93. Kumar, S. et al., Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia, 18, 624-627, 2004.
94. Garcia-Sanz, R. et al., The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed=refractory multiple myeloma. Leukemia, 18, 856-863, 2004.
95. Weber, D. et al., Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol, 21, 16-19, 2003.
96. Mascarenhas, R.C. et al., Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma. Oncology, 67, 471-475, 2004.
97. Little, R.F. et al., Activity of thalidomide in AIDS-related Kaposi’s sarcoma. J Clin Oncol, 18, 2593-2602, 2000.
98. Vogt, T. et al., Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer, 98, 2251-2256, 2003.
99. Baumann, F. et al., Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme. J Neuro Oncol, 67, 191-200, 2004.
100. Fine, H.A. et al., Phase II trial of thalidomide and carmustine for patients with recurrent highgrade gliomas. J Clin Oncol, 21, 2299-2304, 2003.
101. Hwu, W.J. et al., Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol, 21, 3351-3356, 2003.
102. Hwu, W.J. et al., Treatment of metastatic melanoma in the brain with temozolomide and thalidomide. Lancet Oncol, 2, 634-635, 2001.
103. Danson, S. et al., Randomized phase II study of temozolomide given every 8 h or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol, 21, 2551-2557, 2003.
104. Hernberg, M. et al., Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. J Clin Oncol, 21, 3770-3776, 2003.
105. Dahut, W.L. et al., Randomized phase II trial of docetaxel plus thalidomide in androgenindependent prostate cancer. J Clin Oncol, 22, 2532-2539, 2004.
106. Robinson-Rechavi, M. et al., How many nuclear hormone receptors are there in the human genome? Trends Genet, 17, 554-556, 2001.
107. Fajas, L. et al., The organization, promoter analysis, and expression of the human PPAR gamma gene. J Biol Chem, 272, 18779-18789, 1997.
108. Forman, B.M. et al., 15-Deoxy-delta 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell, 83, 803-812, 1995.
109. Yki-Jarvinen, H., Thiazolidinediones. N Engl J Med, 351, 1106-1118, 2004.
110. Grommes, C., Landreth, G.E., and Heneka, M.T., Antineoplastic effects of peroxisome proliferatoractivated receptor gamma agonists. Lancet Oncol, 5, 419-429, 2004.
111. Palakurthi, S.S. et al., Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res, 61, 6213-6218, 2001.
112. Mueller, E. et al., Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA, 97, 10990-10995, 2000.
113. Mueller, E. et al., Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell, 1, 465-470, 1998.
114. Elstner, E. et al., Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA, 95, 8806-8811, 1998.
115. Ricote, M. et al., The peroxisome proliferator-activated receptor (PPAR gamma) as a regulator of monocyte=macrophage function. J Leukoc Biol, 66, 733-739, 1999.
116. Zhang, X. et al., Peroxisome proliferator-activated receptor-gamma and its ligands attenuate biologic functions of human natural killer cells. Blood, 104, 3276-3284, 2004.
117. Szatmari, I. et al., Activation of PPAR gamma specifies a dendritic cell subtype capable of enhanced induction of iNKT cell expansion. Immunity, 21, 95-106, 2004.
118. Sunami, E. et al., Decreased synthesis of matrix metalloproteinase-7 and adhesion to the extracellular matrix proteins of human colon cancer cells treated with troglitazone. Surg Today, 32, 343-350, 2002.
119. Galli, A. et al., Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPAR gamma independent mechanisms. Gut, 53, 1688-1697, 2004.
120. Barak, Y. et al., PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell, 4, 585-595, 1999.
121. Panigrahy, D. et al., PPAR gamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest, 110, 923-932, 2002.
122. Yamakawa, K. et al., Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem Biophys Res Commun, 271, 571-574, 2000.
123. Jozkowicz, A. et al., Ligands of peroxisome proliferator-activated receptor-gamma increase the generation of vascular endothelial growth factor in vascular smooth muscle cells and in macrophages. Acta Biochim Pol, 47, 1147-1157, 2000.
124. Goetze, S. et al., Leptin induces endothelial cell migration through Akt, which is inhibited by PPAR gamma-ligands. Hypertension, 40, 748-754, 2002.
125. Douros, J. and Suffness, M., New antitumor substances of natural origin. Cancer Treat Rev, 8, 63-87, 1981.
126. Huang, S. and Houghton, P.J., Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs, 3, 295-304, 2002.
127. Wiederrecht, G.J. et al., Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells. Prog Cell Cycle Res, 1, 53-71, 1995.
128. Hosoi, H. et al., Rapamycin causes poorly reversible inhibition of mTOR and induces p53- independent apoptosis in human rhabdomyosarcoma cells. Cancer Res, 59, 886-894, 1999.
129. Oldham, S. and Hafen, E., Insulin=IGF and target of rapamycin signaling: a TOR de force in growth control. Trends Cell Biol, 13, 79-85, 2003.
130. Carraway, H. and Hidalgo, M., New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res, 6, 219-224, 2004.
131. Jacinto, E. and Hall, M.N., Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol, 4, 117-126, 2003.
132. Beugnet, A. et al., Regulation of targets of mTOR (mammalian target of rapamycin) signalling by intracellular amino acid availability. Biochem J, 372, 555-566, 2003.
133. Peng, T., Golub, T.R., and Sabatini, D.M., The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol, 22, 5575-5584, 2002.
134. Proud, C.G., Regulation of mammalian translation factors by nutrients. Eur J Biochem, 269, 5338-5349, 2002.
135. Huang, S. and Houghton, P.J., Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol, 3, 371-377, 2003.
136. Shi, Y. et al., Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res, 62, 5027-5034, 2002.
137. Huang, S. et al., p53=p21 (CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. Cancer Res, 61, 3373-3381, 2001.
138. Dennis, P.B. et al., Mammalian TOR: a homeostatic ATP sensor. Science, 294, 1102-1105, 2001.
139. Dutcher, J.P., Mammalian target of rapamycin inhibition. Clin Cancer Res, 10, 6382S-6387S, 2004.
140. Dilling, M.B. et al., 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem, 277, 13907-13917, 2002.
141. Hidalgo, M. and Rowinsky, E.K., The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene, 19, 6680-6686, 2000.
142. Harada, H. et al., p70S6 kinase signals cell survival as well as growth, inactivating the proapoptotic molecule BAD. Proc Natl Acad Sci USA, 98, 9666-9670, 2001.
143. Schmelzle, T. and Hall, M.N., TOR, a central controller of cell growth. Cell, 103, 253-262, 2000.
144. Rosenwald, I.B. et al., Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels. J Biol Chem, 270, 21176-21180, 1995.
145. Hudson, C.C. et al., Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol, 22, 7004-7014, 2002.
146. Rao, R.D., Buckner, J.C., and Sarkaria, J.N., Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. Curr Cancer Drug Targets, 4, 621-636, 2004.
147. Luan, F.L. et al., Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int, 63, 917-926, 2003.
148. Gibbons, J.J. et al., The effect of CCI-779, a novel macrolide antitumor agent, on the growth of human tumor cells in vitro and in nude mouse xenograft in vivo. Proc Am Assoc Cancer Res, 40, 301, 2000.
149. Koehl, G.E. et al., Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation, 77, 1319-1326, 2004.
150. Yu, K. et al., mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer, 8, 249-258, 2001.
151. Frost, P. et al., In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood, 104, 4181-4187, 2004.
152. El-Hashemite, N. et al., Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res, 63, 5173-5177, 2003.
153. Guba, M. et al., Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis:involvement of vascular endothelial growth factor. Nat Med, 8, 128-135, 2002.
154. Humar, R. et al., Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J, 16, 771-780, 2002.
155. Bruns, C.J. et al., Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res, 10, 2109-2119, 2004.
156. Bagli, E. et al., Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 30-kinase activity. Cancer Res, 64, 7936-7946, 2004.
157. Tsutsumi, N. et al., Essential role of PDGFRalpha-p70S6K signaling in mesenchymal cells during therapeutic and tumor angiogenesis in vivo: role of PDGFRalpha during angiogenesis. Circ Res, 94, 1186-1194, 2004.
158. Koehl, G. et al., Rapamycin treatment at immunosuppressive doses affects tumor blood vessel circulation. Transplant Proc, 35, 2135-2136, 2003.
159. Dutcher, J.P., Mammalian target of rapamycin (mTOR) inhibitors. Curr Oncol Rep, 6, 111-115, 2004.
160. Atkins, M.B. et al., Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol, 22, 909-918, 2004.
161. Chan, S., Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer, 91, 1420-1424, 2004.
162. Hanahan, D., Bergers, G., and Bergsland, E., Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest, 105, 1045-1047, 2000.
163. Man, S. et al., Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res, 62, 2731-2735, 2002.
164. Kerbel, R.S. and Kamen, B.A., The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer, 4, 423-436, 2004.
165. Eberhard, A. et al., Heterogeneity of angiogenesis and blood vessel maturation in human tumors:implications for antiangiogenic tumor therapies. Cancer Res, 60, 1388-1393, 2000.
166. Miller, K.D., Sweeney, C.J., and Sledge, G.W., Jr., Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol, 19, 1195-1206, 2001.
167. Browder, T. et al., Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res, 60, 1878-1886, 2000.
168. Lennernas, B. et al., Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals: a quantitative study. APMIS, 112, 201-209, 2004.
169. Kerbel, R.S. et al., Continuous low-dose anti-angiogenic=metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol, 13, 12-15, 2002.
170. Hahnfeldt, P., Folkman, J., and Hlatky, L., Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol, 220, 545-554, 2003.
171. Wang, J. et al., Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs, 14, 13-19, 2003.
172. Hirata, S. et al., Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum, 32, 1065-1073, 1989.
173. Bocci, G., Nicolaou, K.C., and Kerbel, R.S., Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res, 62, 6938-6943, 2002.
174. Grant, D.S. et al., Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer, 104, 121-129, 2003.
175. Klement, G. et al., Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res, 8, 221-232, 2002.
176. Drevs, J. et al., Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res, 24, 1759-1763, 2004.
177. Bocci, G. et al., Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA, 100, 12917-12922, 2003.
178. Hamano, Y. et al., Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res, 64, 1570-1574, 2004.
179. de Fraipont, F. et al., Thrombospondins and tumor angiogenesis. TrendsMol Med, 7, 401-407, 2001.
180. Lawler, J., Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med, 6, 1-12, 2002.
181. Gupta, K. et al., Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis, 3, 147-158, 1999.
182. Rapisarda, A. et al., Schedule-dependent inhibition of hypoxia-inducible factor-1 alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res, 64, 6845-6848, 2004.
183. Asahara, T. et al., Isolation of putative progenitor endothelial cells for angiogenesis. Science, 275, 964-967, 1997.
184. Asahara, T. et al., Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res, 85, 221-228, 1999.
185. Murayama, T. et al., Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor-induced neovascularization in vivo. Exp Hematol, 30, 967-972, 2002.
186. Takahashi, T. et al., Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med, 5, 434-438, 1999.
187. Hattori, K. et al., Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med, 193, 1005-1014, 2001.
188. Heeschen, C. et al., Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood, 102, 1340-1346, 2003.
189. Bertolini, F. et al., Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res, 63, 4342-4346, 2003.
190. Ben-Efraim, S., Immunomodulating anticancer alkylating drugs: targets and mechanisms of activity. Curr Drug Targets, 2, 197-212, 2001.
191. Matar, P. et al., Th2=Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol Immunother, 50, 588-596, 2002.
192. Garber, K., Could less be more? Low-dose chemotherapy goes on trial. J Natl Cancer Inst, 94, 82-84, 2002.
193. Sterba, J., Pavelka, Z., and Slampa, P., Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors. Neoplasma, 49, 117-120, 2002.
194. Kurzen, H. et al., Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs, 14, 515-522, 2003.
195. Colleoni, M. et al., Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer:antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol, 13, 73-80, 2002.
196. Sandri, M.T. et al., Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma. Anticancer Res, 24, 1261-1266, 2004.
197. Glode, L.M. et al., Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer, 98, 1643-1648, 2003.
198. Nicolini, A. et al., Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomed Pharmacother, 58, 447-450, 2004.
199. Niitsu, N. and Umeda, M., Evaluation of long-term daily administration of oral low-dose etoposide in elderly patients with relapsing or refractory non-Hodgkin’s lymphoma. Am J Clin Oncol, 20, 311-314, 1997.
200. Gunsilius, E. et al., Palliative chemotherapy in pretreated patients with advanced cancer: oral trofosfamide is effective in ovarian carcinoma. Cancer Invest, 19, 808-811, 2001.
201. Kollmannsberger, C. et al., Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma. Anticancer Drugs, 10, 453-456, 1999.
202. Pietras, K. and Hanahan, D., A multitargeted, metronomic, and maximum-tolerated dose “Chemo-Switch” regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol, 23, 939-952, 2005.
203. Rozados, V.R. et al., Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity. Ann Oncol, 15, 1543-1550, 2004.
204. Emmenegger, U. et al., A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res, 64, 3994-4000, 2004.
205. Strumberg, D. et al., Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5-fluorouracil. Anticancer Drugs, 8, 293-295, 1997.
206. Reichle, A. et al., Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer, 101, 2247-2256, 2004.
207. Yu, J.L. et al., Heterogeneous vascular dependence of tumor cell populations. Am J Pathol, 158, 1325-1334, 2001.
208. Kerbel, R.S. et al., Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev, 20, 79-86, 2001.
209. Graeber, T.G. et al., Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature, 379, 88-91, 1996.
210. Relf, M. et al., Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res, 57, 963-969, 1997.
211. Rak, J. et al., What do oncogenic mutations have to do with angiogenesis=vascular dependence of tumors? Cancer Res, 62, 1931-1934, 2002.
212. Eggert, A. et al., High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res, 6, 1900-1908, 2000.
213. Huang, J. et al., Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res, 2, 36-42, 2004.
214. Korff, T. et al., Blood vessel maturation in a 3-dimensional spheroidal coculture model: direct contact with smooth muscle cells regulates endothelial cell quiescence and abrogates VEGF responsiveness. FASEB J, 15, 447-457, 2001.
215. Oike, Y. et al., Regulation of vasculogenesis and angiogenesis by EphB=ephrin-B2 signaling between endothelial cells and surrounding mesenchymal cells. Blood, 100, 1326-1333, 2002.
216. Coras, B. et al., Antiangiogenic therapy with pioglitazone, rofecoxib, and trofosfamide in a patient with endemic kaposi sarcoma. Arch Dermatol, 140, 1504-1507, 2004.
217. Reichle, A. et al., Anti-inflammatory and angiostatic therapy in chemorefractory multisystem Langerhans’ cell histiocytosis of adults. Br J Haematol, 128, 730-732, 2005.
218. Reichle, A. et al., Metronomic chemotherapy plus=minus antiinflammatory treatment in faradvanced melanoma: a randomized multi-institutional phase II trial. Proc Am Soc Clin Oncol, A3139, 2005.
219. Giovannucci, E., The prevention of colorectal cancer by aspirin use. Biomed Pharmacother, 53, 303-308, 1999.
220. Lundholm, K. et al., Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int J Oncol, 24, 505-512, 2004.
221. Tuettenberg, J. et al., Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol, 131, 31-40, 2005.
222. Hada, M. and Mizutari, K., [A case report of metastatic pancreatic cancer that responded remarkably to the combination of thalidomide, celecoxib and irinotecan]. Gan To Kagaku Ryoho, 31, 1407-1410, 2004.
223. Raje, N. et al., Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood, 104, 4188-4193, 2004.
224. DeCicco, K.L. et al., The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines:possible involvement in the PPAR gamma pathway. Carcinogenesis, 25, 1805-1812, 2004.
225. Badawi, A.F. et al., Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma. Cancer Res, 64, 1181-1189, 2004.
226. Michael, M.S., Badr, M.Z., and Badawi, A.F., Inhibition of cyclooxygenase-2 and activation of peroxisome proliferator-activated receptor-gamma synergistically induces apoptosis and inhibits growth of human breast cancer cells. Int J Mol Med, 11, 733-736, 2003.
227. Li, M.Y. et al., PPAR gamma pathway activation results in apoptosis and COX-2 inhibition in HepG2 cells. World J Gastroenterol, 9, 1220-1226, 2003.
228. Sabichi, A.L. et al., Peroxisome proliferator-activated receptor-gamma suppresses cyclooxygenase-2 expression in human prostate cells. Cancer Epidemiol Biomarkers Prev, 13, 1704-1709, 2004.
229. Han, S. et al., Control of COX-2 gene expression through peroxisome proliferator-activated receptor gamma in human cervical cancer cells. Clin Cancer Res, 9, 4627-4635, 2003.
230. Grau, R., Iniguez, M.A., and Fresno, M., Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-delta12,14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-gamma-independent mechanism. Cancer Res, 64, 5162-5171, 2004.
231. Wick, M. et al., Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal antiinflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol Pharmacol, 62, 1207-1214, 2002.
232. Folkman, J., Endogenous angiogenesis inhibitors. APMIS, 112, 496-507, 2004.
233. Crawford, S.E. et al., Captopril suppresses post-transplantation angiogenic activity in rat allograft coronary vessels. J Heart Lung Transplant, 23, 666-673, 2004.
234. Volpert, O.V. et al., Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest, 98, 671-679, 1996.
235. Folkman, J. et al., Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science, 221, 719-725, 1983.
236. Folkman, J. and Shing, Y., Control of angiogenesis by heparin and other sulfated polysaccharides. Adv Exp Med Biol, 313, 355-364, 1992.
237. Norrby, K., Heparin and angiogenesis: a low-molecular-weight fraction inhibits and a highmolecular- weight fraction stimulates angiogenesis systemically. Haemostasis, 23 Suppl 1, 141-149, 1993.
238. Presta, M. et al., Antiangiogenic activity of semisynthetic biotechnological heparins: lowmolecular- weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists. Arterioscler Thromb Vasc Biol, 25, 71-76, 2005.
239. Burstein, H.J. et al., Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat, 79, 391-397, 2003.
240. Ferrandina, G. et al., Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosisrelated marker, and microvessel density in human cervical cancer: a pilot study. Clin Cancer Res, 9, 4324-4331, 2003.
241. Milella, M. et al., Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer, 101, 133-138, 2004.